Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Pheon Therapeutics has raised $120.0M in total funding. The most recent round was Series B. The last funding was announced in May 2024.
Pheon Therapeutics's investors include Lightspeed Venture Partners, Brandon Capital, Perceptive Advisors, Atlas Venture, Forbion Capital Partners.
Pheon Therapeutics is headquartered in London, United Kingdom.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Pheon Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pheon Therapeutics — Funding & Investors." VCBacked, May 21, 2024, https://www.vcbacked.co/company/pheon-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Pheon Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/pheon-therapeutics
{{cite web |title=Pheon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/pheon-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated